Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck And J&J Settle Remicade Dispute By Redrawing The Map

This article was originally published in The Pink Sheet Daily

Executive Summary

Rather than let an arbitration panel decide the fate of two anti-TNF drugs, Merck surrenders many territories but holds onto Europe.

You may also be interested in...

FDA Approves Simponi For Ulcerative Colitis

J&J received approval to market a second TNF inhibitor to treat the bowel disorder. The authorization comes as Simponi’s increasing sales point toward blockbuster status.

J&J Says Penalties In Arkansas Risperdal Case ‘Excessive,’ Seeks New Trial

Argues that Arkansas Medicaid spent less than $10 million on Risperdal, but the fine imposed by a state judge for deceptive marketing practices would exceed $1.2 billion.

FDA Warns Again Of Rare Cancer Associated With TNF Blockers

FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts